Antibacterial Drugs Market Progresses for Huge Profits by 2026 Antibacterial Drugs Market - Global Forecast to 2026, by Drug class (Beta lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, Phenicols, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026 The Global Antibacterial Drugs Market size was valued at US$ 43,791.2 million in 2017, and is expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026). Antibacterial drugs are used in treatment or prohibition of bacterial infections caused due to various factors such as climatic changes, unhygienic lifestyle specially in emerging economies and others. Major challenge associated with antibacterial drugs is resistance of bacteria towards it. Significant studies are carried out to develop new antibacterial drugs to combat these problems. Market Dynamics Increasing prevalence of infectious diseases is a major factor driving antibacterial drugs market growth. According to World Health Organization (WHO), September 2018, annually around 11 million to 21 million cases of typhoid fever are reported worldwide. Moreover, growing geriatric population susceptible to high risk of bacterial infection, majorly caused due to age related changes in immunology is expected to boost the market growth. The Current Opinion in Microbiology Journal 2016, stated Lower respiratory tract infection (Pneumonia), as the most common cause of infection disease in older patients in the U.S. and estimated it as 6 leading cause of death in the U.S. However, price control of antibacterial drugs, genetic mutation in aging population, and decrease in financial incentives has distracted the focus of pharmaceutical companies from research and development of antibacterial drugs. In September 2016, AstraZeneca announced an agreement with Pfizer to sell the development and commercialization rights to its late-stage small molecule antibiotics business as AstaZeneca does not find antibiotic research as major area for development in their business. Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/177 Increasing incidences of infectious diseases is expected to propel growth of the antibacterial drugs market Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries. Moreover, initiatives by government concerned to antibacterial resistance is expected to propel market growth over the forecast period. For instance, in May 2018, the UK government announced fund of US$ 34 million to fight against antimicrobial resistance (AMR). This funding will be distributed to the 4 projects such as Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator of US$ 23 million, Global Antibiotic Research and Development Partnership invested US$ 1 million, and US$ 5 million for two project such as bilateral partnership with Argentina and Foundation for Innovative New Diagnostics. Detailed Segmentation: •Global Antibacterial Drugs Market, By Drug class: •Beta lactams •Quinolones Macrolides •Tetracycline •Aminoglycoside •Sulfonamide •Phenicols •Others •Global Antibacterial Drugs Market, By Route of Administration: •Oral •Topical •Parenteral •Others Key Players Major players operating in the global antibacterial drugs market include Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc. Increasing population and high incidences of infectious diseases in North America are expected to bolster the market growth North America holds dominant position in the global antibacterial drugs market, owing to rising population base susceptible to infectious diseases and higher incidences of infectious diseases such as tuberculosis and others. According to the Centers for Disease Control and Prevention (CDC), in 2017, an estimated 9,105 patients were diagnosed with tuberculosis in the U.S. Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients diagnosed with infectious diseases. For instance, in February 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Egaten, used for the treatment of Fascioliasis caused by Fasciola hepatica infection. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: sales@coherentmarketinsights.com
The Global Antibacterial Drugs Market size was valued at US$ 43,791.2 million in 2017, and is expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026). Antibacterial drugs are used in treatment or prohibition of bacterial infections caused due to various factors such as climatic changes, unhygienic lifestyle specially in emerging economies and others.
© Copyright 2024 Paperzz
